{
    "clinical_study": {
        "@rank": "138001", 
        "acronym": "PERCI-MCO", 
        "arm_group": [
            {
                "arm_group_label": "MCO-Ci 400", 
                "arm_group_type": "Experimental", 
                "description": "MCO-Ci 400 is the investigational medical product applied in hemodialysis mode"
            }, 
            {
                "arm_group_label": "Revaclear 400", 
                "arm_group_type": "Active Comparator", 
                "description": "the standard high flux dialyzer Revaclear 400 is used as  an comparator in hemodialysis mode"
            }
        ], 
        "brief_summary": {
            "textblock": "The medium cut-off dialysis membrane has been developed to provide a significantly extended\n      molecular cut-off compared to conventional high-flux membranes. The medium cut-off membrane\n      allows for a high permeability of molecules up to a molecular weight of 45 kDa and has a\n      still limited permeability for albumin (68 kDa).\n\n      The main goal of this project is the evaluation of the new, highly porous and selective\n      dialysis membrane (MCO-Ci 400) for the treatment of patients with end-stage renal disease in\n      hemodialysis mode and to study its potential to improve chronic inflammation."
        }, 
        "brief_title": "PERCI- Medium Cut Off (MCO)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Kidney Failure", 
            "Chronic Inflammation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Inflammation", 
                "Kidney Failure, Chronic", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  CKD5 ( GFR < 15ml/min/ 1.73m2)\n\n          -  Dialysis treatment for \u2265 3 months\n\n          -  Dialysis 3x weekly\n\n          -  Vascular access by fistula or CVC\n\n          -  Age > 18 and < 99 Years\n\n          -  Ability to give written informed consent\n\n        Exclusion Criteria:\n\n          -  Missing informed consent form\n\n          -  current clinically manifested infection or within the last two weeks\n\n          -  current CRP-value > 50mg/L or within the last two weeks\n\n          -  Intake of any medication applied for immunosuppressive purposes\n\n          -  Pregnancy or lactation\n\n          -  Participation in a different interventional study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02084381", 
            "org_study_id": "1502"
        }, 
        "intervention": [
            {
                "arm_group_label": "MCO-Ci 400", 
                "description": "hemodialysis", 
                "intervention_name": "MCO-Ci 400", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Revaclear 400", 
                "description": "hemodialysis", 
                "intervention_name": "Revaclear 400", 
                "intervention_type": "Device", 
                "other_name": "standard high flux dialyzer"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "CKD5, dialysis, high porous membranes", 
        "lastchanged_date": "March 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "matthias.girndt@medizin.uni-halle.de", 
                    "last_name": "Girndt, Prof. Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "Halle", 
                        "country": "Germany", 
                        "state": "Sachsen-Anhalt", 
                        "zip": "06120"
                    }, 
                    "name": "Martin-Luther-Universit\u00e4t Halle-Wittenberg"
                }, 
                "investigator": {
                    "last_name": "Matthias Girndt, Prof. Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ralf.schindler@charite.de", 
                    "last_name": "Schindler, Prof. Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13353"
                    }, 
                    "name": "Charit\u00e9 - Universit\u00e4tsmedizin Berlin"
                }, 
                "investigator": {
                    "last_name": "Ralf Schindler, Prof. Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Permeability Enhancement to Reduce Chronic Inflammation _ Medium Cut Off (MCO) (Study no 1502)", 
        "other_outcome": {
            "description": "Elimination of inflammatory molecules and uremic toxins from patient's blood", 
            "measure": "Exploratory", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "overall_contact": {
            "email": "matthias.girndt@medizin.uni-halle.de", 
            "last_name": "Matthias Girndt, Prof. Dr.", 
            "phone": "+ 49 (0) 345/5572717"
        }, 
        "overall_contact_backup": {
            "email": "ralf.schindler@charite.de", 
            "last_name": "Ralf Schindler, Prof. Dr.", 
            "phone": "+ 49 (0) 30 450/653132"
        }, 
        "overall_official": {
            "affiliation": "Martin-Luther-Universit\u00e4t Halle-Wittenberg", 
            "last_name": "Matthias Girndt, Prof. Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Significant lower pre- dialytic TNF-\u03b1 mRNA expression level in circulating peripheral blood mononuclear cells", 
            "measure": "TNF-alpha mRNA", 
            "safety_issue": "No", 
            "time_frame": "4 weeks treatment time"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02084381"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "safety related events", 
            "safety_issue": "Yes", 
            "time_frame": "6 month"
        }, 
        "source": "Gambro Dialysatoren GmbH", 
        "sponsors": {
            "collaborator": {
                "agency": "German Federal Ministry of Education and Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Gambro Dialysatoren GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}